About: Effect of licorice on patients with HSD11B1 gene polymorphisms- a pilot study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Effect of licorice on patients with HSD11B1 gene polymorphisms- a pilot study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Effect of licorice on patients with HSD11B1 gene polymorphisms- a pilot study
Creator	Adhikari, Prabha Devang, Nayana Nandini, M Rai, Padmalatha Satyamoorthy, Kapaettu
topic	covid:3acfa98585629d97232f4b3f47cedfab150fd13e#this
Source	Elsevier; Medline; PMC
abstract	The positive association of HSD11B1 gene polymorphism with type 2 diabetes (T2D) and prediabetic conditions has been revealed. In the current study, we assessed the effectiveness of licorice on the clinical profile of the patients with HSD11B1 gene polymorphism. Licorice (Glycyrrhiza Glabra) is a competitive inhibitor of 11 beta-hydroxysteroid dehydrogenase 1 (11β-HSD1) enzyme and has been traditionally reported as an anti-ulcer, anti-pyretic, anti-thirst, anti-inflammatory, hypoglycemic and hypolipidemic agent. The aim of the study was to assess the effectiveness of licorice on the clinical profile of participants with HSD11B1 gene polymorphism. The study was performed using diabetic patients with HSD11B1 gene polymorphism. Biochemical and anthropometric parameters were measured using standard diagnostic tools. Fourteen patients were divided into two groups by simple randomization, Licorice group (treated with 750 mg licorice/day for three weeks), and placebo group (treated with 750 mg placebo/day for three weeks). Investigations were repeated at the end of three weeks. Licorice showed a significant reduction in serum insulin levels (p = 0.03). There was no significant change in any other clinical parameters either by licorice or placebo. Conclusively, licorice moderately improves serum insulin levels in patients with HSD11B1 gene polymorphism. From our pilot study, the safety of licorice is confirmed at a dose of 750 mg/day. However, the study can be repeated at a higher dose to show its effectiveness and safety.
has issue date	2020-08-12(xsd:dateTime)
bibo:doi	10.1016/j.jaim.2020.06.006
bibo:pmid	32800398
has license	no-cc
sha1sum (hex)	3acfa98585629d97232f4b3f47cedfab150fd13e
schema:url	https://doi.org/10.1016/j.jaim.2020.06.006
resource representing a document's title	Effect of licorice on patients with HSD11B1 gene polymorphisms- a pilot study
has PubMed Central identifier	PMC7422817
has PubMed identifier	32800398
schema:publication	J Ayurveda Integr Med
resource representing a document's body	covid:3acfa98585629d97232f4b3f47cedfab150fd13e#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/3acfa98585629d97232f4b3f47cedfab150fd13e
is schema:about of	named entity 'conditions' named entity 'Glycyrrhiza Glabra' named entity 'effectiveness' named entity 'patients' named entity 'treated' named entity 'performed' named entity 'The' named entity 'gene' named entity 'http' named entity 'PARTICIPANTS' named entity 'THREE WEEKS' named entity 'ENZYME' named entity 'DIABETIC' named entity 'HYPOLIPIDEMIC AGENT' named entity 'IS A' named entity 'WITH TYPE' named entity 'INSULIN LEVELS' named entity 'EFFECTIVENESS' named entity 'TYPE 2 DIABETES' named entity 'MG%' named entity 'CONFIRMED' named entity 'FOURTEEN' named entity 'OUR' named entity 'polymorphism' named entity 'licorice' named entity 'repeated' named entity 'polymorphism' named entity 'The' named entity 'type 2 diabetes' named entity 'profile' named entity 'day' named entity 'Biochemical' named entity 'pilot study' named entity 'license' named entity 'pilot' named entity 'licorice' named entity 'prediabetic' named entity 'Licorice' named entity 'serum' named entity 'insulin' named entity 'gene polymorphism' named entity 'anti-inflammatory' named entity 'Licorice' named entity 'licorice' named entity 'T2D' named entity 'gene polymorphism' named entity 'pilot study' named entity 'HSD11B1' named entity 'gene polymorphism' named entity 'inflammation' named entity 'Licorice' named entity 'anti-inflammatory agent' named entity 'total cholesterol' named entity 'insulin' named entity 'blood clotting' named entity 'Congestive heart failure' named entity 'licorice' named entity 'standard deviation' named entity 'antipyretic' named entity 'gene polymorphism' named entity 'FBS' named entity 'blood sugar' named entity 'licorice' named entity 'Clinical trial' named entity 'body fat' named entity 'licorice' named entity 'anti-ulcer' named entity 'informed consent' named entity 'virus' named entity 'IL-6' named entity 'HPTLC' named entity 'digitalis' named entity 'T2D' named entity 'host cell' named entity 'Himalaya'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software